DOCSLIB.ORG

The Alcohol Withdrawal Syndrome

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Alcohol Withdrawal Syndrome Downloaded from jnnp.bmj.com on February 13, 2010 - Published by group.bmj.com The alcohol withdrawal syndrome A McKeon, M A Frye and Norman Delanty J Neurol Neurosurg Psychiatry 2008 79: 854-862 originally published online November 6, 2007 doi: 10.1136/jnnp.2007.128322 Updated information and services can be found at: http://jnnp.bmj.com/content/79/8/854.full.html These include: References This article cites 115 articles, 40 of which can be accessed free at: http://jnnp.bmj.com/content/79/8/854.full.html#ref-list-1 Email alerting Receive free email alerts when new articles cite this article. Sign up in the service box at the top right corner of the online article. Topic collections Articles on similar topics can be found in the following collections Memory disorders (neurology) (2797 articles) Epilepsy and seizures (4241 articles) Unwanted effects / adverse reactions (945 articles) Alcohol-related disorders (1568 articles) Delirium (1255 articles) Drugs misuse (including addiction) (2940 articles) Memory disorders (psychiatry) (4300 articles) Drugs: musculoskeletal and joint diseases (8176 articles) Notes To order reprints of this article go to: http://jnnp.bmj.com/cgi/reprintform To subscribe to Journal of Neurology, Neurosurgery & Psychiatry go to: http://jnnp.bmj.com/subscriptions Downloaded from jnnp.bmj.com on February 13, 2010 - Published by group.bmj.com Review The alcohol withdrawal syndrome A McKeon,1 M A Frye,2 Norman Delanty1 1 Department of Neurology and ABSTRACT every 26 hospital bed days being attributable to Clinical Neurosciences, The alcohol withdrawal syndrome (AWS) is a common some degree of alcohol misuse.5 Despite this Beaumont Hospital, Dublin, and management problem in hospital practice for neurologists, Royal College of Surgeons in substantial problem, a survey of NHS general Ireland, Dublin, Ireland; psychiatrists and general physicians alike. Although some hospitals conducted in 2000 and 2003 indicated 2 Department of Psychiatry, patients have mild symptoms and may even be managed that only 12.8% had a dedicated alcohol worker.6 In Mayo Clinic, Rochester, MN, in the outpatient setting, others have more severe addition, few guidelines exist promoting the USA symptoms or a history of adverse outcomes that requires initiation of clear and uniform AWS treatment 7–9 Correspondence to: close inpatient supervision and benzodiazepine therapy. protocols. Andrew McKeon, Department of Many patients with AWS have multiple management Neurology, Gonda 8 South, issues (withdrawal symptoms, delirium tremens, the PATHOPHYSIOLOGY Mayo Clinic, 200 1st St Sw, Wernicke–Korsakoff syndrome, seizures, depression, Rochester, MN 55905, USA; Alcohol has an effect on multiple neurotransmitter [email protected] polysubstance abuse, electrolyte disturbances and liver disease), which requires a coordinated, multidisciplinary systems in the brain. Pharmacological, electrophy- siological (both often undertaken in a rat model of Received 25 June 2007 approach. Although AWS may be complex, careful Revised 12 October 2007 evaluation and available treatments should ensure safe ethanol withdrawal) and genetic studies have Accepted 17 October 2007 detoxification for most patients. helped to elucidate the mechanisms of AWS. Published Online First Acute alcohol ingestion has an inhibitory effect at 6 November 2007 N-methyl-D-aspartate (NMDA) receptors, redu- cing excitatory glutamatergic transmission,10 11 The alcohol withdrawal syndrome (AWS) consists and has an agonistic effect at gamma-aminobutyric of symptoms and signs arising in alcohol-depen- acid type-A (GABA ) receptors. During prolonged dent individuals, typically within 24–48 hours of A exposure to alcohol, NMDA receptors are upregu- consumption of their last drink. Although AWS lated and GABA receptors are downregulated, occurs intentionally in those seeking abstinence, it A leading to tolerance.12 The roles are reversed during may arise unexpectedly in an alcohol-dependent abstinence, with enhanced NMDA receptor func- patient, after an admission to hospital. Although tion, reduced GABAergic transmission and dysre- alcohol withdrawal is common and usually mild, gulation of the dopaminergic system, leading to the abrupt cessation of alcohol consumption by a many of the symptoms and signs of AWS.13 14 patient with alcohol dependence may lead to Although GABA levels increase in both plasma delirium tremens (a severe dysautonomic and and CSF during withdrawal,15 symptoms of with- encephalopathic state) and withdrawal seizures, drawal still evolve due to downregulation of both of which may be fatal. The following should GABA receptors during prior prolonged alcohol be addressed by the treating doctor (fig 1): A exposure. GABA and GABA mechanisms are also confirming the diagnosis; choosing an appropriate A B critical for the development of anxiety-like beha- drug regimen and setting for management of viour that is induced by repeated ethanol intoxica- alcohol withdrawal; monitoring for and treating tions and withdrawals16. Altered numbers and other complications related to alcohol dependence functions of NMDA (particularly NR1 and NR2B (including Wernicke’s encephalopathy (WE), phy- subtypes17) and GABA receptors resulting from sical trauma and depression). In this paper, we A chronic alcohol exposure may be partly responsible review the literature on AWS, and discuss our for alcohol withdrawal seizures. Electro- views regarding an approach to management. physiologically, alterations in neurotransmitter receptor function translate into an absence of EPIDEMIOLOGY inhibitory postsynaptic potentials and currents in The prevalence of alcohol withdrawal in the ethanol-withdrawn rats.18 In addition, voltage- general population is low (,5% in US adults in dependent calcium influx modulates neurotrans- 1995), but is higher among those admitted for mitter release and expression of genes that regulate detoxification and rehabilitation for alcohol abuse production of NMDA and GABA receptor proteins; (up to 86%).1 In a UK national survey conducted in the continued presence of alcohol increases vol- 2002, 38% of male respondents and 23% of female tage-operated calcium channel expression and respondents self-reported hazardous drinking (5 or contributes to alcohol tolerance and AWS.19 more drinks for a man or 3 or more drinks for a Acamprosate, an abstinence-promoting drug, prob- woman) on a typical drinking day.2 However, in ably has its effect through antagonism of gluta- the setting of medical practice, this figure is higher, mate receptor subtype-5 and NMDA receptors, with the prevalence of alcohol abuse or dependence thus inhibiting the rise in glutamate that occurs reaching 20% of hospital inpatients,3 and up to during AWS.20 Dopaminergic transmission is 40% of patients attending Accident and Emergency enhanced during AWS (high plasma homo- departments.4 The cost of alcoholism is a large vallinic acid has been observed in patients with burden on the UK economy, and was estimated to delirium tremens21) and may play a role in cost the NHS £1.5 billion in 2000/2001, with 1 in hallucination formation;22 23 increased dopamine 854 J Neurol Neurosurg Psychiatry 2008;79:854–862. doi:10.1136/jnnp.2007.128322 Downloaded from jnnp.bmj.com on February 13, 2010 - Published by group.bmj.com Review By definition, the patient must have two or more of the following after cessation or reduction of alcohol use that has been heavy or prolonged: autonomic hyperactivity (sweating, tachycardia); increased hand tremor; insomnia; nausea or vomiting; transient visual, tactile, or auditory hallucinations or illusions; psychomotor agitation; anxiety and tonic-clonic seizures. Although, often, AWS is mild and does not require treatment, if severe it may be complicated by alcohol with- drawal seizures and delirium tremens (characterised by a severe hyperadrenergic state, disorientation, impaired attention and consciousness, as well as visual and auditory hallucinations).31 The chronic heavy user of alcohol is the typical patient who develops alcohol withdrawal seizures, which are thought to occur secondary to a kindling effect of recurrent detoxifica- tions.32 Although distinct from a true alcohol withdrawal seizure, young people with primary generalised epilepsy may present with a seizure in association with alcohol consumption and sleep deprivation on the previous night. In order to establish the risk of developing AWS and its complications, and to identify other alcohol-related problems, a Figure 1 Algorithm for management of uncomplicated alcohol careful alcohol history should be obtained. This allows for early withdrawal. detection, prevention and treatment of AWS. The components of the alcohol history are: estimating consumption (types of alcoholic drink consumed, volume, frequency and drinking receptor-binding density (D2 in the dorsal striatum and D1 in pattern); establishing if the patient is alcohol dependent the amygdala) has also been observed.24 The potential impor- (daily drinking, drinking early in the day, rating the priority tance of the amygdala and the striatum in the pathophysiology of alcohol in the patient’s life, previous medical interventions of alcohol withdrawal has also been suggested by persisting high required in relation to drinking); and establishing whether levels of cyclic guanosine 39,59-monophosphate (cGMP) in these 25 problems have arisen in relation to drinking (social, domestic, regions in rats. Neurons in the deep layers of the superior emotional, occupational,
Load more

Recommended publications
  • Alcohol Intoxication & Intervention Scale
    Alcohol Intoxication & Intervention Scale Alcohol affects each individual differently. The effect of alcohol on a person will vary according to the person's mood, the time of day, Standard Drink amount of food in the stomach, the mixer used, how fast the person One standard drink of beer drinks, and what and why they are drinking. There are a variety of One 12 oz bottle of beer positive and negative consequences related to drinking. One 12 oz can of beer One 8 oz glass of malt liquor (i.e. Blood Alcohol Level Old English, Mickey's) Once you know the definition of one standard drink (see chart to the One standard drink of wine right), you can estimate your Blood Alcohol Level (BAL). BAL levels One 4 oz glass of wine (pictured) represent the percent of your blood that is concentrated with alcohol. A One 3 ‐ 3.5 oz of fortified wine (i.e. BAL of .10 means that .1% of your bloodstream is composed of alcohol. port, sherry) One bottle of table wine is about 5 Some key factors that affect BAL: standard drinks How many standard drinks you drink One standard drink of hard alcohol Remember different drinks have different strengths either One 1.25 oz shot of hard liquor because of differences in proofs of hard liquor or because some (pictured) drinks contain more than one shot One mixed drink containing one 1.25 oz shot of hard liquor Food eaten along with drinking alcohol will result in a lower, One 750ml bottle of hard liquor ("a delayed BAL because the alcohol enters the bloodstream at a fifth") is about 17 standard drinks lower rate Intoxication and Intervention Scale Know the visible signs of intoxication.
    [Show full text]
  • Alcohol Intoxication Withdrawal Adult
    Provincial Clinical Knowledge Topic Alcohol Intoxication Withdrawal, Adult Emergency Department V 1.5 © 2018, Alberta Health Services. This work is licensed under the Creative Commons Attribution-Non-Commercial-No Derivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. Disclaimer: This material is intended for use by clinicians only and is provided on an "as is", "where is" basis. Although reasonable efforts were made to confirm the accuracy of the information, Alberta Health Services does not make any representation or warranty, express, implied or statutory, as to the accuracy, reliability, completeness, applicability or fitness for a particular purpose of such information. This material is not a substitute for the advice of a qualified health professional. Alberta Health Services expressly disclaims all liability for the use of these materials, and for any claims, actions, demands or suits arising from such use. Document History Version Date Description of Revision Completed By / Revised By 1.1 July 2015 Completed document (2013) reformatted into Dr. Bullard / Carla new topic template Milligan 1.2 January Minor edits in the Rationale section and form 1 Dr. Bullard / Sarah 2016 info in general care section as well as addition Searle of CIWA-Ar Scoring Reference tool to appendix 1.3 May 2016 Minor edits made to working group Sarah Searle membership list 1.4 June Removed link to Center for Addiction and Dr. Bullard / Sarah 2017 Mental Health assessment and documentation Searle form on pg. 35. Documentation requirements will continue as per local practice at this time.
    [Show full text]
  • Gabitril® (Tiagabine)
    Gabitril (Tiagabine) What is Gabitril (Tiagabine)? Gabitril is an anti-epileptic drug that has been used to treat patients with epilepsy since 1997. It is helpful in the treatment of partial seizures. Starting the Medicine: We usually gradually increase the dose, until your body gets adjusted to the medication. Since each patient is unique in that he/she breaks down the medication differently or may need a higher or lower dosage to control their seizures, there is no standard dose that is appropriate for all patients. What dosages does the pill come in and what does it look like? 4 mg round, yellow tablet 12 mg oval, green tablet 16 mg oval, blue tablet 20 mg oval, pink tablet What Side Effects Can Be Caused By Gabitril? Side effects can be dose related (common) or idiosyncratic (rare): Common Dose - Related Side Effects: Dizziness, drowsiness, difficulty concentrating, or nausea may occur. If you have these side effects, your doctor may: • spread out the dose more frequently during the day • slow the rate of dose increase Comprehensive Epilepsy Center (734) 936-9020 - 1 - • instruct you to take the pills with food since this will slow the rate at which the medicine gets into the blood, but will not affect the total amount that is absorbed. Rare Side Effects: Rare side effects may include: difficulty sleeping, nervousness, or balance problems. Skin Rash: An allergic reaction, or rash, may occur with Gabitril. If this occurs, notify your doctor immediately. Pregnancy: Currently, no information is available about the effects of Gabitril during pregnancy. Any woman taking Gabitril should discuss this issue with her doctor BEFORE becoming pregnant.
    [Show full text]
  • Mechanisms of Ethanol-Induced Cerebellar Ataxia: Underpinnings of Neuronal Death in the Cerebellum
    International Journal of Environmental Research and Public Health Review Mechanisms of Ethanol-Induced Cerebellar Ataxia: Underpinnings of Neuronal Death in the Cerebellum Hiroshi Mitoma 1,* , Mario Manto 2,3 and Aasef G. Shaikh 4 1 Medical Education Promotion Center, Tokyo Medical University, Tokyo 160-0023, Japan 2 Unité des Ataxies Cérébelleuses, Service de Neurologie, CHU-Charleroi, 6000 Charleroi, Belgium; [email protected] 3 Service des Neurosciences, University of Mons, 7000 Mons, Belgium 4 Louis Stokes Cleveland VA Medical Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44022, USA; [email protected] * Correspondence: [email protected] Abstract: Ethanol consumption remains a major concern at a world scale in terms of transient or irreversible neurological consequences, with motor, cognitive, or social consequences. Cerebellum is particularly vulnerable to ethanol, both during development and at the adult stage. In adults, chronic alcoholism elicits, in particular, cerebellar vermis atrophy, the anterior lobe of the cerebellum being highly vulnerable. Alcohol-dependent patients develop gait ataxia and lower limb postural tremor. Prenatal exposure to ethanol causes fetal alcohol spectrum disorder (FASD), characterized by permanent congenital disabilities in both motor and cognitive domains, including deficits in general intelligence, attention, executive function, language, memory, visual perception, and commu- nication/social skills. Children with FASD show volume deficits in the anterior lobules related to sensorimotor functions (Lobules I, II, IV, V, and VI), and lobules related to cognitive functions (Crus II and Lobule VIIB). Various mechanisms underlie ethanol-induced cell death, with oxidative stress and Citation: Mitoma, H.; Manto, M.; Shaikh, A.G. Mechanisms of endoplasmic reticulum (ER) stress being the main pro-apoptotic mechanisms in alcohol abuse and Ethanol-Induced Cerebellar Ataxia: FASD.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Tiagabine Synergistically Interacts with Gabapentin in the Electroconvulsive Threshold Test in Mice
    Neuropsychopharmacology (2003) 28, 1817–1830 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Tiagabine Synergistically Interacts with Gabapentin in the Electroconvulsive Threshold Test in Mice 1,5 2 3 ,1,4 Jarogniew J Łuszczki , Mariusz S´ wia˛der , Jolanta Parada-Turska and Stanisław J Czuczwar* 1 2 Department of Pathophysiology, Medical University, Lublin, Poland; Department of Pharmacology and Toxicology, Medical University, Lublin, 3 4 Poland; Department of Rheumatology, Medical University, Lublin, Poland; Isotope Laboratory, Institute of Agricultural Medicine, Lublin, Poland Polytherapy, based on the rational combining of antiepileptic drugs (AEDs), is required for patients with drug-resistant epilepsy. In such cases, the combinations of AEDs usually offer a significant enhancement of their protective effects against seizures. There has appeared a hypothesis that combining two AEDs, influencing the same neurotransmitter system, results in the potentialization of their anticonvulsant effects. For corroborating this hypothesis, a pharmacological character of interaction between tiagabine (TGB) and gabapentin F (GBP) two novel AEDs affecting the GABA-ergic system, in the maximal electroshock seizure threshold (MEST)-test in mice was evaluated. TGB at the dose of 4 mg/kg and GBP at 75 mg/kg significantly raised the electroconvulsive threshold. Further, using the isobolographic calculations, TGB was coadministered with GBP at three fixed-ratios (1 : 3, 1 : 1, and 3 : 1) of their respective protective drug doses. All examined combinations of TGB with GBP exerted supra-additive (synergistic) interactions against MEST-induced seizures in mice. The interaction index, describing the strength and magnitude of interaction, ranged between 0.25 and 0.50 indicating supra- additivity.
    [Show full text]
  • Shared Care Guideline for Tiagabine (Gabitril®) for Use As Add on Therapy for Partial Seizures in Adults and Children Over 12
    Dorset Medicines Advisory Group SHARED CARE GUIDELINE FOR TIAGABINE (GABITRIL®) FOR USE AS ADD ON THERAPY FOR PARTIAL SEIZURES IN ADULTS AND CHILDREN OVER 12 INDICATION Licensed indications & therapeutic class Tiagabine is an anti-epileptic drug indicated as add-on therapy for partial seizures with or without secondary generalisation where control is not achieved by optimal doses of at least one other anti- epileptic drug. Tiagabine is licensed only for use in adults and children over the age of 12. It is not licensed for monotherapy. NICE CG137: Epilepsies: diagnosis and management (page 26) states: Offer carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate or topiramate as adjunctive treatment to children, young people and adults with focal seizures if first-line treatments [carbamazepine or lamotrigine, levetiracetam, oxcarbazepine or sodium valoprate] are ineffective or not tolerated. If adjunctive treatment is ineffective or not tolerated, discuss with, or refer to, a tertiary epilepsy specialist. Other AEDs that may be considered by the tertiary epilepsy specialist are eslicarbazepine acetate, lacosamide, phenobarbital, phenytoin, pregabalin, tiagabine, vigabatrin and zonisamide. Carefully consider the risk–benefit ratio when using vigabatrin because of the risk of an irreversible effect on visual fields. NICE also has a “Do not do” recommendation in relation to tiagabine: “Do not offer carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine or vigabatrin as adjunctive treatment in children, young people and adults with childhood absence epilepsy, juvenile absence epilepsy or other absence epilepsy syndromes.” AREAS OF RESPONSIBILITY FOR SHARED CARE Patients should be at the centre of any shared care arrangements. Individual patient information and a record of their preferences should accompany shared care prescribing guidelines, where appropriate.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • An Open-Label Study to Evaluate Switching from an SSRI Or SNRI To
    Annals of Clinical Psychiatry, 19[1]:25–30, 2007 Copyright © American Academy of Clinical Psychiatrists ISSN: 1040-1237 print / 1547-3325 online DOI: 10.1080/10401230601163535 AnUACP Open-Label Study to Evaluate Switching from an SSRI or SNRI to Tiagabine to Alleviate Antidepressant- Induced Sexual Dysfunction in Generalized Anxiety Disorder THOMASEffect of Tiagabine on sexual dysfunction in GAD L. SCHWARTZ, MD Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA GEORGE S. NASRA, MD Unity Behavioral Health, Rochester, NY, USA ADAM K. ASHTON, MD Department of Psychiatry, SUNY Buffalo School of Medicine, Buffalo, NY, USA DAVID KANG, MD, HARI KUMARESAN, MD, MARK CHILTON, MS, and FRANCESCA BERTONE, BA Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA Background. This study investigated tiagabine monotherapy in subjects with generalized anxiety disorder (GAD) who had been switched from selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) as a result of antidepressant-induced sexual dysfunction. Methods. Adults with DSM-IV GAD, an adequate therapeutic response (≥50% decrease in Hamilton Rating Scale for Anxiety [HAM-A] total score) to SSRI or SNRI and sexual dysfunction were switched to open-label tiagabine 4–12 mg/day for 14 weeks. Assessments included the HAM-A, Hospital Anxiety & Depression Scale (HADS) and the Arizona Sexual Experiences Scale (ASEX); assessments were made at baseline and at Weeks 4, 8, and 14. Results. Twenty six subjects were included in the analysis. Tiagabine showed no worsening in baseline symptoms of GAD, with non-significant changes from baseline in mean HAM-A total scores and HADS Anxiety and Depression subscale scores.
    [Show full text]
  • Pharmacokinetic and Pharmacodynamic Interactions Between Antiepileptics and Antidepressants Domenico Italiano University of Messina, Italy
    University of Kentucky UKnowledge Psychiatry Faculty Publications Psychiatry 11-2014 Pharmacokinetic and Pharmacodynamic Interactions between Antiepileptics and Antidepressants Domenico Italiano University of Messina, Italy Edoardo Spina University of Messina, Italy Jose de Leon University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/psychiatry_facpub Part of the Psychiatry and Psychology Commons Repository Citation Italiano, Domenico; Spina, Edoardo; and de Leon, Jose, "Pharmacokinetic and Pharmacodynamic Interactions between Antiepileptics and Antidepressants" (2014). Psychiatry Faculty Publications. 40. https://uknowledge.uky.edu/psychiatry_facpub/40 This Article is brought to you for free and open access by the Psychiatry at UKnowledge. It has been accepted for inclusion in Psychiatry Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact [email protected]. Pharmacokinetic and Pharmacodynamic Interactions between Antiepileptics and Antidepressants Notes/Citation Information Published in Expert Opinion on Drug Metabolism & Toxicology, v. 10, Issue 11, p. 1457-1489. © 2014 Taylor & Francis Group This is an Accepted Manuscript of an article published by Taylor & Francis Group in Expert Opinion on Drug Metabolism & Toxicology in Nov. 2014, available online: http://www.tandfonline.com/10.1517/ 17425255.2014.956081 Digital Object Identifier (DOI) http://dx.doi.org/10.1517/17425255.2014.956081 This article is available at UKnowledge: https://uknowledge.uky.edu/psychiatry_facpub/40 1 This is an Accepted Manuscript of an article published by Taylor & Francis Group in Expert Opinion on Drug Metabolism & Toxicology in Nov.
    [Show full text]
  • Court Intervention: Pre-Sentence Investigation
    If you have issues viewing or accessing this file contact us at NCJRS.gov. ------~--- ---- .. National Criminal Justice Reference Service COURT INTERVENTION: PRE-SENTENCE This microfiche was 'produced from documents received for inclusion in the NCJRS data base. Since NCJRS cannot exercise control over the physical condition of the documents submitted, INVESTIGATION the individual frame quality will vary. The resolution chart on this frame may be used to evaluate the document quality. TECHNIQUES FOR DRINKING/DRIVING OFFENSES 2 8 1.0 :; 11111 . 111111:~ W IIp·2 .2 W I.r.: I~ w: J:,i 14.0 ..,.I.::. u. - 1.1 tIl&.:.u - , == I 111111.25 11111·1.4 111111.6 I ! I MICROCOPY RESOLUTION TEST CHART NATIONAL BUREAU OF STANDARDS-1963-A .. ' ~ ...,.. '~'''';'''' ..' .. ~" - q P ARTI'CIPANT'S Microfil~ing proced~;~~~sed to create this fiche comply with & the standards set forth i1141CFR lOl-11.SD4. MANUAL Points of view or opinions stated in this document are those of the author(s) and do not represent the official U.S. Department of Transportation DATE FILMED ~ National Highway Traffic Safety Administration position or policies of the U. S. Department of Justice. Washington, D.C. 20590 '-, . ~ , .... ~ 1. _ .I. ' 1 9/04/81' " National Institute of Justice -;: .J.____ .... United States Department of Justice Washington, D. C. 2053<1 • , --~---.~--~. --- ~ I ! CONTENTS SEMINAR AGENDA iii ; - l AGENDA PRE-SENTENCE INVESTIGATION SEMINAR Day One 0900-1200 1. Introduction and Overview UNITS 1. Introduction and Overview 1 i: This unit covers: (a) introduction and administrative infor­ 2. The Problem Drinking Drive 9 mation, (b) information on DOT/NHTSA standards, (c) the genesis of the project, and (d) explanation of the ASAP 3.
    [Show full text]
  • Background Paper 6.14 Harmful Use of Alcohol Alcohol Use Disorders and Alcoholic Liver Diseases
    Priority Medicines for Europe and the World "A Public Health Approach to Innovation" Update on 2004 Background Paper Written by Warren Kaplan, Ph.D, JD, MPH Background Paper 6.14 Harmful use of Alcohol Alcohol Use Disorders and Alcoholic Liver Diseases By Rene Soria Saucedo (MD, MPH, PhDc) January 2013 Update on 2004 Background Paper, BP 6.14 Alcohol Use Disorders Table of Contents Abbreviations: ..................................................................................................................................................... 5 Executive Summary ............................................................................................................................................ 6 Burden of Disease ............................................................................................................................................ 6 Treatment Options ........................................................................................................................................... 7 1. Introduction ................................................................................................................................................. 8 1.1 Alcohol Consumption (ACo) and its relationship with Alcohol Use Disorders (AUD) ........... 8 1.2 Alcohol Use Disorders (AUD) .......................................................................................................... 9 1.3 Alcoholic Liver Diseases (ALD) .....................................................................................................
    [Show full text]